Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.

ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...

The first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...

Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ...

Four papers published in JAMA, JAMA Neurology and JAMA Network Open look at Amyotrophic Lateral Sclerosis (ALS) treatment results from the HEALY ALS Platform Trial. Dr Ahmad Al Khleifat, Senior ...

Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some promising results.

Now comes Kirton and his advisory council’s most ambitious project, the virtual ALS Super Auction, between Feb. 6-20. Every NHL team is offering a package for bidding, centred around game tickets, ...

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone treatment, results of an administrative claims analysis show."Since ALS has ...

This data is being collected from ongoing Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial. The company plans to submit an NDA for ALS in mid-2025. The company reported $14.6 ...